A first-in-class antibiotic compound designed for topical treatment of early-stage diabetic foot ulcers and other bacterial infections, targeting ACP synthase to disrupt bacterial lipid metabolism.

A novel antibiotic effective against Gram-positive bacteria and, in combination with colistin, against Gram-negative bacteria, targeting ACP synthase to combat multi-drug-resistant infections.